- BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business Update
- BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipeline
- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
- BridgeBio Pharma Announces Pricing of Public Offering of Common Stock
- BridgeBio Pharma Announces Proposed Public Offering of Common Stock
- BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM
- BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
- BridgeBio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in Japan
- BridgeBio Pharma Announces U.S. Food and Drug Administration (FDA) Acceptance of New Drug Application (NDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
More ▼
Key statistics
On Friday, BridgeBio Pharma Inc (BBIO:NSQ) closed at 27.83, 118.27% above the 52 week low of 12.75 set on May 25, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 28.45 |
---|---|
High | 28.78 |
Low | 27.17 |
Bid | 27.13 |
Offer | 28.18 |
Previous close | 27.74 |
Average volume | 1.56m |
---|---|
Shares outstanding | 187.13m |
Free float | 144.46m |
P/E (TTM) | -- |
Market cap | 5.21bn USD |
EPS (TTM) | -3.23 USD |
Data delayed at least 15 minutes, as of May 03 2024 21:00 BST.
More ▼